The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
IL-22 As A Suppressor Of Pancreatic ?-Cell Stress And A Treatment For Diabetes
Funder
National Health and Medical Research Council
Funding Amount
$854,490.00
Summary
Type 2 diabetes occurs when pancreatic beta cells fail to produce enough insulin to control blood sugar levels. We have discovered that the IL-22 protein produced by immune cells protects beta cells from stress. Diabetic mice given IL-22 show restored control of blood sugar levels. The proposed research will take steps to safely introduce IL-22 based therapy into the clinic and gain a deeper understanding of the mechanisms of action of IL-22.
Elucidation Of The Mechanism Of IL-22-Mediated Suppression Of Β-Cell Stress In Diabetes
Funder
National Health and Medical Research Council
Funding Amount
$222,322.00
Summary
Pancreatic ?-cells produce the hormone insulin that controls blood sugar. Type 2 diabetes is characterized by inability of stressed ?-cells to make sufficient insulin to control blood sugar. We discovered that an immune factor, IL-22, protects ?-cells from stress. Treatment of diabetic mice with IL-22 resolves all the major problems in diabetes. This project seeks to reveal the mechanisms by which IL-22 protects ?-cells from stress, with potential for development of novel diabetes therapies.
Pancreatic Targeting Of IL-22 Therapy For Diabetes
Funder
National Health and Medical Research Council
Funding Amount
$484,644.00
Summary
Type 2 diabetes is one of the largest problems facing health care and presents an enormous therapeutic market. Our approach with IL-22 fights the disease at the core of the problem in the pancreatic ?-cells that make insulin. Our patent focuses on targeting IL-22 to the ?-cells which promises to maximise therapeutic benefits while minimising potential adverse effects in other tissues. Independently, and in collaboration with Novo Nordisk, we are making prototype drugs to achieve this.
Pancreatic Islet Inflammation And Its Role In Diabetes And Islet Transplantation
Funder
National Health and Medical Research Council
Funding Amount
$707,370.00
Summary
Diabetes is a major health epidemic & diabetic complications are a major cause of morbidity and mortality in our community. My studies have increased our understanding of how inflammation contributes to diabetes but also directly led to the discovery of novel therapies that are been trialed in patients with type 1 diabetes undergoing islet cell transplants. My studies have increased our knowledge of the factors that lead to type 1 diabetes and the development of new treatments.
I am a clinical epidemiologist with a breadth of training and experience in medical oncology, general medicine, biostatistics and clinical trials. My research encompasses providing leadership in the design and conduct of clinical trials aimed at improvin